Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.87
Dollar change
-0.30
Percentage change
-9.46
%
Index- P/E- EPS (ttm)-1.34 Insider Own31.24% Shs Outstand186.96M Perf Week-7.42%
Market Cap536.75M Forward P/E- EPS next Y-0.47 Insider Trans0.17% Shs Float128.60M Perf Month8.71%
Income-111.57M PEG- EPS next Q-0.11 Inst Own62.23% Short Float12.30% Perf Quarter65.42%
Sales15.45M P/S34.74 EPS this Y57.71% Inst Trans-1.76% Short Ratio5.80 Perf Half Y-3.37%
Book/sh0.40 P/B7.16 EPS next Y-14.94% ROA-56.40% Short Interest15.81M Perf Year340.18%
Cash/sh0.77 P/C3.72 EPS next 5Y- ROE-294.04% 52W Range0.50 - 3.89 Perf YTD62.15%
Dividend Est.- P/FCF- EPS past 5Y-137.69% ROI-83.01% 52W High-26.22% Beta0.28
Dividend TTM- Quick Ratio4.06 Sales past 5Y129.39% Gross Margin86.86% 52W Low474.00% ATR (14)0.32
Dividend Ex-Date- Current Ratio4.06 EPS Y/Y TTM64.68% Oper. Margin-461.94% RSI (14)56.39 Volatility10.11% 12.57%
Employees52 Debt/Eq0.82 Sales Y/Y TTM517.55% Profit Margin-722.06% Recom1.33 Target Price6.06
Option/ShortYes / Yes LT Debt/Eq0.79 EPS Q/Q125.84% Payout- Rel Volume1.10 Prev Close3.17
Sales Surprise23.41% EPS Surprise331.76% Sales Q/Q44.04% EarningsMar 19 AMC Avg Volume2.73M Price2.87
SMA205.88% SMA5034.16% SMA20052.14% Trades Volume3,011,651 Change-9.46%
Date Action Analyst Rating Change Price Target Change
Feb-01-23Downgrade Jefferies Buy → Hold $14 → $1.50
Jan-27-23Downgrade Morgan Stanley Overweight → Equal-Weight $23 → $3
Nov-09-22Downgrade Goldman Buy → Neutral $16 → $3
Mar-09-22Initiated Robert W. Baird Outperform $26
Mar-01-22Initiated Wells Fargo Overweight $25
Feb-18-22Initiated SMBC Nikko Outperform $25
Dec-16-21Initiated Guggenheim Buy $28
Jul-16-21Initiated Needham Buy $45
Jun-24-21Initiated Truist Buy $60
Jun-15-21Initiated BTIG Research Buy $44
Mar-20-24 11:19AM
08:01AM
Mar-19-24 08:53PM
04:01PM
Mar-14-24 04:26PM
05:08PM Loading…
Mar-01-24 05:08PM
Feb-29-24 08:00AM
Feb-15-24 04:01PM
Feb-02-24 08:00AM
Jan-31-24 02:23PM
Jan-22-24 08:00AM
Jan-15-24 09:30AM
Jan-10-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 07:30AM
08:00AM Loading…
Nov-29-23 08:00AM
Nov-15-23 02:00PM
12:52PM
Nov-14-23 06:35PM
04:08PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-10-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 04:01PM
Sep-05-23 09:55AM
Sep-04-23 03:04PM
Aug-24-23 08:00AM
Aug-15-23 01:54AM
Aug-14-23 07:02AM
07:00AM Loading…
07:00AM
Jul-31-23 08:00AM
Jul-18-23 07:08AM
Jun-28-23 08:00AM
Jun-15-23 08:00AM
Jun-05-23 08:00AM
May-19-23 12:54PM
08:00AM
May-16-23 11:41AM
May-12-23 10:15AM
May-11-23 04:01PM
May-04-23 08:00AM
Apr-27-23 04:52PM
Apr-15-23 08:24AM
Mar-30-23 06:08AM
Mar-28-23 04:01PM
Mar-15-23 04:01PM
Feb-14-23 05:32PM
Feb-08-23 05:42AM
Jan-31-23 04:01PM
Jan-24-23 02:32PM
Dec-19-22 02:05PM
Dec-16-22 06:19PM
Dec-01-22 09:55AM
Nov-29-22 04:01PM
Nov-08-22 07:00AM
Nov-03-22 08:26PM
Nov-02-22 07:00AM
Oct-26-22 07:54PM
11:05AM
06:13AM
Oct-25-22 04:01PM
03:55PM
09:31AM
08:15AM
Oct-24-22 07:35PM
07:30PM
Oct-06-22 07:00AM
Aug-29-22 07:35AM
Aug-12-22 08:30AM
Aug-11-22 07:00AM
Aug-09-22 05:22PM
Aug-01-22 07:00AM
Jul-19-22 08:39AM
Jul-06-22 07:00AM
Jun-13-22 08:39AM
Jun-02-22 07:00AM
May-16-22 08:00PM
07:00AM
May-11-22 07:00AM
May-10-22 07:00AM
May-07-22 10:57AM
May-03-22 07:00AM
Apr-25-22 07:00AM
Apr-18-22 08:00AM
Apr-04-22 10:16AM
Mar-31-22 06:29PM
05:30PM
01:31PM
07:00AM
Mar-29-22 07:00AM
Mar-24-22 07:00AM
Mar-23-22 07:00AM
Mar-16-22 11:14AM
Mar-08-22 07:00AM
Feb-10-22 04:50PM
09:47AM
Feb-09-22 05:00PM
Jan-31-22 07:00AM
Jan-12-22 08:00AM
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning Paul B10% OwnerNov 17 '23Buy1.63100,000163,00016,566,667Nov 20 07:35 AM
Alam KamranChief Financial OfficerAug 24 '23Sale2.3333,00076,890258,042Aug 25 04:30 PM
Manning Paul B10% OwnerAug 16 '23Buy0.9016,466,66714,820,00016,466,667Aug 16 08:57 PM
Nolan Sean P.Chief Executive OfficerAug 16 '23Buy0.90444,444400,0001,535,545Aug 16 08:52 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000884,290Aug 16 08:53 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000999,381Aug 16 08:53 PM
Donenberg Phillip B.DirectorAug 16 '23Buy0.90111,111100,000114,111Aug 16 08:51 PM
Session R.A. II10% OwnerJul 13 '23Sale0.705,3443,7418,871,747Jul 14 04:00 PM
Session R.A. II10% OwnerJul 12 '23Sale0.7180,52857,0308,877,091Jul 14 04:00 PM
Session R.A. II10% OwnerJun 23 '23Sale0.7018,10012,7358,957,619Jun 26 04:46 PM
Session R.A. II10% OwnerJun 22 '23Sale0.7010,5087,3848,975,719Jun 26 04:46 PM
Session R.A. II10% OwnerJun 21 '23Sale0.70138,96297,6358,986,227Jun 22 04:00 PM
Session R.A. II10% OwnerJun 20 '23Sale0.71295,653210,2099,125,189Jun 22 04:00 PM
Nagendran SukumarPresident and Head of R&DMay 16 '23Buy0.685,0003,40034,226May 18 04:44 PM